|
1
|
Eisenhauer EA: Real-world evidence in the
treatment of ovarian cancer. Ann Oncol. 28 (Suppl 8):viii61–viii65.
2017. View Article : Google Scholar
|
|
2
|
Webb PM and Jordan SJ: Epidemiology of
epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol.
41:3–14. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Nammalwar B, Bunce RA, Berlin KD, Benbrook
DM and Toal C: Synthesis and biological evaluation of SHetA2
(NSC-721689) analogs against the ovarian cancer cell line A2780.
Eur J Med Chem. 170:16–27. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Marchetti C, De Felice F, Perniola G,
Palaia I, Musella A, Di Donato V, Cascialli G, Muzii L, Tombolini V
and Benedetti Panici P: Role of intraperitoneal chemotherapy in
ovarian cancer in the platinum-taxane-based era: A meta-analysis.
Crit Rev Oncol Hematol. 136:64–69. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Andersen RE and Lim DA: Forging our
understanding of lncRNAs in the brain. Cell Tissue Res. 371:55–71.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Huarte M: The emerging role of lncRNAs in
cancer. Nat Med. 21:1253–1261. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Peng WX, Koirala P and Mo YY:
LncRNA-mediated regulation of cell signaling in cancer. Oncogene.
36:5661–5667. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liu X, Wen J, Wang H and Wang Y: Long
non-coding RNA LINC00460 promotes epithelial ovarian cancer
progression by regulating microRNA-338-3p. Biomed Pharmacother.
108:1022–1028. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ye JJ, Cheng YL, Deng JJ, Tao WP and Wu L:
LncRNA LINC00460 promotes tumor growth of human lung adenocarcinoma
by targeting miR-302c-5p/FOXA1 axis. Gene. 685:76–84. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang Y, Liu X, Li Q and Zhang Y: lncRNA
LINC00460 promoted colorectal cancer cells metastasis via
miR-939-5p sponging. Cancer Manag Res. 11:1779–1789. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ma G, Zhu J, Liu F and Yang Y: Long
Noncoding RNA LINC00460 promotes the gefitinib resistance of
nonsmall cell lung cancer through epidermal growth factor receptor
by sponging miR-769-5p. DNA Cell Biol. 38:176–183. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang F, Liang S, Liu X, Han L, Wang J and
Du Q: LINC00460 modulates KDM2A to promote cell proliferation and
migration by targeting miR-342-3p in gastric cancer. OncoTargets
Ther. 11:6383–6394. 2018. View Article : Google Scholar
|
|
13
|
Ge SS, Wu YY, Gao W, Zhang CM, Hou J, Wen
SX and Wang BQ: Expression of long non-coding RNA LINC00460 in
laryngeal squamous cell carcinoma tissue and its clinical
significance. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi.
32:18–22. 2018.(In Chinese). PubMed/NCBI
|
|
14
|
Kong YG, Cui M, Chen SM, Xu Y, Xu Y and
Tao ZZ: LncRNA-LINC00460 facilitates nasopharyngeal carcinoma
tumorigenesis through sponging miR-149-5p to up-regulate IL6. Gene.
639:77–84. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liang Y, Wu Y, Chen X, Zhang S, Wang K,
Guan X, Yang K, Li J and Bai Y: A novel long noncoding RNA
linc00460 up-regulated by CBP/P300 promotes carcinogenesis in
esophageal squamous cell carcinoma. Biosci Rep. 37:372017.
View Article : Google Scholar
|
|
16
|
Zhao G, Fu Y, Su Z and Wu R: How long
non-coding RNAs and MicroRNAs mediate the endogenous RNA Network of
head and neck squamous cell carcinoma: A comprehensive analysis.
Cell Physiol Biochem. 50:332–341. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Vlad C, Dina C, Kubelac P, Vlad D, Pop B
and Achimas Cadariu P: Expression of toll-like receptors in ovarian
cancer. J BUON. 23:1725–1731. 2018.PubMed/NCBI
|
|
18
|
Zhou H, Zhao H, Liu H, Xu X, Dong X and
Zhao E: Influence of carboplatin on the proliferation and apoptosis
of ovarian cancer cells through mTOR/p70s6k signaling pathway. J
BUON. 23:1732–1738. 2018.PubMed/NCBI
|
|
19
|
Yang X, Guo F, Peng Q, Liu Y and Yang B:
Suppression of in vitro and in vivo human ovarian cancer growth by
isoacteoside is mediated via sub-G1 cell cycle arrest, ROS
generation, and modulation of AKT/PI3K/m-TOR signalling pathway. J
BUON. 24:285–290. 2019.PubMed/NCBI
|
|
20
|
Ottevanger PB: Ovarian cancer stem cells
more questions than answers. Semin Cancer Biol. 44:67–71. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ding SS, Li L and Yu CX: Systematic
evaluation of bevacizumab in recurrent ovarian cancer treatment. J
BUON. 19:965–972. 2014.PubMed/NCBI
|
|
22
|
Maduro MR: Potential biomarkers for
ovarian cancer. Reprod Sci. 26:4492019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Worku T, Bhattarai D, Ayers D, Wang K,
Wang C, Rehman ZU, Talpur HS and Yang L: Long non-coding RNAs: The
new horizon of gene regulation in ovarian cancer. Cell Physiol
Biochem. 44:948–966. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fu LL, Li CJ, Xu Y, Li LY, Zhou X, Li DD,
Chen SX, Wang FG, Zhang XY and Zheng LW: Role of lncRNAs as novel
biomarkers and therapeutic targets in ovarian cancer. Crit Rev
Eukaryot Gene Expr. 27:183–195. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
An J, Lv W and Zhang Y: LncRNA NEAT1
contributes to paclitaxel resistance of ovarian cancer cells by
regulating ZEB1 expression via miR-194. OncoTargets Ther.
10:5377–5390. 2017. View Article : Google Scholar
|
|
26
|
Li AH and Zhang HH: Overexpression of
lncRNA MNX1-AS1 is associated with poor clinical outcome in
epithelial ovarian cancer. Eur Rev Med Pharmacol Sci. 21:5618–5623.
2017.PubMed/NCBI
|
|
27
|
Dou Q, Xu Y, Zhu Y, Hu Y, Yan Y and Yan H:
LncRNA FAM83H-AS1 contributes to the radioresistance,
proliferation, and metastasis in ovarian cancer through stabilizing
HuR protein. Eur J Pharmacol. 852:134–141. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang Y, Dun Y, Zhou S and Huang XH:
LncRNA HOXD-AS1 promotes epithelial ovarian cancer cells
proliferation and invasion by targeting miR-133a-3p and activating
Wnt/β-catenin signaling pathway. Biomed Pharmacother. 96:1216–1221.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yuan J, Liu Z and Song R: Antisense lncRNA
As-SLC7A11 suppresses epithelial ovarian cancer progression mainly
by targeting SLC7A11. Pharmazie. 72:402–407. 2017.PubMed/NCBI
|
|
30
|
Dong S, Wang R, Wang H, Ding Q, Zhou X,
Wang J, Zhang K, Long Y, Lu S, Hong T, et al: HOXD-AS1 promotes the
epithelial to mesenchymal transition of ovarian cancer cells by
regulating miR-186-5p and PIK3R3. J Exp Clin Cancer Res.
38:1102019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li K, Sun D, Gou Q, Ke X, Gong Y, Zuo Y,
Zhou JK, Guo C, Xia Z, Liu L, et al: Long non-coding RNA linc00460
promotes epithelial-mesenchymal transition and cell migration in
lung cancer cells. Cancer Lett. 420:80–90. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yue QY and Zhang Y: Effects of Linc00460
on cell migration and invasion through regulating
epithelial-mesenchymal transition (EMT) in non-small cell lung
cancer. Eur Rev Med Pharmacol Sci. 22:1003–1010. 2018.PubMed/NCBI
|
